EGFR and pachyonychia congenita: Since the expression of MSLN is closely associated with the high expression of cell surface epidermal growth-factor receptor (EGFR) in PC cells [53], we used a clinical grade anti-EGFR Ab (Cetuximab, C255) for its binding to FcBP-LGA-PEI NPs, achieving targeting delivery of TNAs in PC cells with high expression of EGFR.